Please Wait
Applying Filters...
menu
    • menu
    Medical Breakthroughs in 2024: Alzheimer’s, schizophrenia, COPD, MASH see pathbreaking treatments

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

    Stock Recap
    #PipelineProspector

    Menu

    Nilvadipine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    28/10/2024 Astellas Pharma
    Japan
    		 FUJISAWA PHARMACEUTICAL CO LTD 6052 NILVADIPINE (FK 235,FR 34235) 1985-10-07 Inactive II N/A
    28/10/2024 Astellas Pharma
    Japan
    		 FUJISAWA PHARMACEUTICAL CO LTD 14287 NILVADIPINE 1999-07-12 Inactive II N/A